Atea Pharmaceuticals (AVIR) Revenue (2021)
Atea Pharmaceuticals (AVIR) posted quarterly Revenue of $192.2 million for Q4 2021, up 485.72% quarter-over-quarter from $32.8 million in Q3 2021.
Powered by 
Analysis
Atea Pharmaceuticals (AVIR) Revenue (2021) Analysis & Trends
Atea Pharmaceuticals' Revenue history runs 1 years deep, the most recent figure standing at $192.2 million for Q4 2021.
- In Q4 2021, Revenue changed N/A year-over-year to $192.2 million; the TTM figure through Dec 2021 stood at $351.4 million (changed N/A YoY), while the FY2021 annual figure was $351.4 million, up 622.49% from the prior year.
- Revenue for Q4 2021 stood at $192.2 million, up from $32.8 million in the prior quarter.
- The five-year high for Revenue was $192.2 million in Q4 2021, with the low at $32.8 million in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Atea Pharmaceuticals | 467.50 Mn | 467.50 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 192.18 Mn |
| Sep 30, 2021 | 32.81 Mn |
| Jun 30, 2021 | 60.39 Mn |
| Mar 31, 2021 | 65.99 Mn |